Incidence of SARS-CoV-2 Infection Among Patients Undergoing Active Antitumor Treatment in Italy

JAMA Oncol. 2021 Feb 1;7(2):304-306. doi: 10.1001/jamaoncol.2020.6778.

Authors

Carlo Aschele¹, Maria Emanuela Negru¹, Alessandro Pastorino¹, Luigi Cavanna², Vittorina Zagonel³, Francesco Barone-Adesi^{4

5}, Livio Blasi⁶

Affiliations

¹ Medical Oncology Unit, Department of Oncology, Ospedale Sant'Andrea, La Spezia, Italy.
² Department of Oncology-Hematology, G. da Saliceto Hospital, Piacenza, Italy.
³ Oncology Unit 1, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.
⁴ Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
⁵ CRIMEDIM - Research Center in Emergency and Disaster Medicine, Università del Piemonte Orientale, Novara, Italy.
⁶ Medical Oncology Unit, Ospedale Civico, Arnas, Palermo.

Abstract

This cohort study examines rates of SARS-CoV-2 infection among patients with cancer receiving antitumor treatment.

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use*
Antineoplastic Agents, Hormonal / therapeutic use
Antineoplastic Agents, Immunological / therapeutic use
Breast Neoplasms / drug therapy
Breast Neoplasms / epidemiology
COVID-19 / epidemiology*
COVID-19 / physiopathology
Colorectal Neoplasms / drug therapy
Colorectal Neoplasms / epidemiology
Female
Hospitalization
Humans
Immunotherapy
Italy / epidemiology
Lung Neoplasms / drug therapy
Lung Neoplasms / epidemiology
Male
Middle Aged
Molecular Targeted Therapy
Neoplasms / drug therapy*
Neoplasms / epidemiology
Prostatic Neoplasms / drug therapy
Prostatic Neoplasms / epidemiology
SARS-CoV-2

Substances

Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents, Immunological